Zinzino AB Class B

Zinzino AB Class B

13.83
USD
-0.01
(-0.11%)
1.13EPS
12.41P/E
570.72MMarket Cap
Nov 17Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.4
12.12
14.48
15.27
16.58
16.36
21.82
32.7
38.4
40.2
49.42
61.26
88.94
98.97
Basic EPS, GAAP
0.33
1.01
0.27
0.28
-0.03
0.13
0.33
1.96
2.57
2.01
4.83
4.95
9.09
11.38
Free Cash Flow per Basic Share
-0.16
1.6
-0.07
0.04
1.02
0.65
1.98
2.81
4.29
0.53
6.92
8.46
14.86
18.86
Dividend per Share
- -
0.09
0.25
0.25
0.25
0.45
0.7
0.7
1.26
2
1.75
3.01
4.01
6.28
Book Value per Share
0.8
2.79
2.68
2.52
1.65
1.32
1.01
2.65
4.24
4.56
7.66
11.07
19.45
27.54
Tangible Book Value per Share
0.67
0.89
0.76
0.74
0.12
-0.24
-0.54
0.96
2.36
0.99
4.15
6.02
9.21
11.3
Basic Weighted Avg Shares
27
30
31
31
33
33
33
33
34
34
34
34
36
37
Sales/Revenue/Turnover
255
358
444
479
540
533
711
1,074
1,288
1,356
1,675
2,094
3,172
3,678
Operating Margin (%)
4.52
5.51
6.39
3.38
0.56
1.2
2.08
8.06
8.51
6.41
12.47
10.5
12.93
14.62
Depreciation Expense
1
2
7
8
9
17
19
22
22
25
32
31
33
43
Net Income, GAAP
9
30
8
9
-1
4
11
64
86
68
164
169
324
423
Effective Tax Rate (%)
5.34
- -
44.97
30.27
203.17
17.57
18.61
21.98
21.94
23.2
21.91
22.77
22.54
22.16
Profit Margin (%)
3.55
8.37
1.85
1.82
-0.21
0.77
1.5
6
6.69
4.99
9.78
8.08
10.22
11.5
Working Capital
15
19
20
24
-9
-21
-33
24
65
38
145
174
370
424
LT Debt
- -
- -
- -
- -
31
41
33
34
25
37
42
35
30
38
Total Equity
23
86
88
88
61
50
40
95
152
160
264
386
707
1,080
Return on Invested Capital (%)
47.78
- -
10.76
10.34
-1
4.96
12.09
51.85
44.48
27.86
53.16
38.46
46.05
48.89
Return on Capital (%)
46.91
- -
8.11
8.82
-1.8
4.17
11.68
57.35
50.36
33.7
61.62
44.73
54.39
51.52
Return on Common Equity (%)
53.85
57.67
9.94
10.56
-1.65
8.44
28
107.07
74.8
45.51
79.02
52.42
59.41
55.5

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
22
24
25
LT Borrowings
10
- -
- -
LT Finance Leases
20
43
38
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
39
39
Market Capitalization
5,811
5,642
5,533

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,306
1,503
1,464
Cash, Cash Equivalents & STI
770
889
842
Accounts Receivable, Net
15
100
114
Inventories
378
414
424
Total Current Liabilities
936
984
1,040
Payables & Accruals
- -
- -
- -
ST Debt
22
24
25
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
32.67%
52%
83.14%
Free Cash Flow
380.47%
256.47%
83.28%
Net Income, GAAP
34.35%
49.82%
91.71%
Sales/Revenue/Turnover
22.91%
25.04%
51.48%
Total Cash Common Dividend
38.56%
48.77%
38.99%

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
454
507
532
713
2,094
2025
724
794
784
1,035
3,172
2026
922
937
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.04
1.41
1.24
1.25
4.95
2025
1.61
1.56
2.47
3.41
9.09
2026
2.79
2.72
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
3.02
- -
- -
3.01
2025
- -
4.04
- -
- -
4.01
2026
- -
6.01
- -
- -
- -

Company Description

CEO
Dag Bergheim Pettersen
Full Time Employees
322
Sector
Consumer non-durables
Industry
Food: major diversified
Address
Hulda Mellgrens Gata 5 Gothenburg Sweden 421 32
IPO Date
Sep 20, 2010
Business
Zinzino AB (publ) is a Sweden-based direct sales company specializing in test-based, personalized nutrition, health supplements, skincare and lifestyle products. Founded in 2005 and headquartered in Västra Frölunda, Gothenburg, the company offers biomarker-based health tests including dried blood spot tests for omega-6:3 balance, gut health, vitamin D and blood sugar levels; omega supplements such as BalanceOil+ with fish oil and extra virgin olive oil; immune support products like Xtend with vitamins and minerals; gut health supplements including ZinoBiotic+ with dietary fibers; weight management solutions; collagen gels; the Swiss biotech skincare brand HANZZ+HEIDII featuring cleansers, face creams, serums and masks; and coffee products with machines, accessories and cups. Zinzino operates through the Zinzino and Faun segments, owning Norwegian research and production units BioActive Foods AS and Faun Pharma AS, and sells via online platforms and distributors in over 100 markets across Europe, North America, Asia, Australia, India, Africa, Philippines, China and New Zealand. Recent developments include the acquisitions of Zurvita assets in February 2025 for expanded distribution in the US, Canada and Mexico; Valentus Global in April 2025 to boost European presence; Ecosystem assets in June 2025 enhancing reach in France and DOM-TOM; Bodē Pro in September 2025 for North America and Japan; and Truvy in September 2025 targeting North America, Latin America and South Korea, alongside expansions into new markets and launches like pioneering gut health testing.

Company News

  • ZINZINO AB (PUBL.): YEAR-END REPORT 2025

  • ZINZINO AB (PUBL.): ZINZINO ANNOUNCES PERU AS NEXT STEP IN ITS GLOBAL EXPANSION

  • ZINZINO AB (PUBL): Zinzino announces merger of It Works! into the Zinzino family of businesses for increased distribution power in North America and Europe

  • Zinzino AB (publ.): Interim Report for the third quarter of 2025

  • Zinzino AB (publ.): Zinzino acquires 35% of the shares in Andorra-based Xion International Group for further development of its own-produced omega-3 oil and spirulina

  • Zinzino AB (publ.): Zinzino acquires Mexican company Sanki to increase distribution capacity in North America and South America

  • Zinzino AB (publ.): Pioneering Gut Health Testing With a Simple Finger Prick

  • ZINZINO AB (PUBL.): ZINZINO ACQUIRES TRUVY TO INCREASE DISTRIBUTION CAPACITY IN NORTH AMERICA, LATIN AMERICA, AND SOUTH KOREA

  • ZINZINO AB (PUBL.): INTERIM REPORT FIRST QUARTER 2025

  • ZINZINO AB (PUBL.): Zinzino acquires Valentus Global to increase distribution power in Europe

  • ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT Q1 2025

  • ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT FEBRUARY 2025

  • ZINZINO AB (PUBL.): YEAR-END REPORT 2024

  • ZINZINO AB (PUBL.): ANNOUNCES ACQUISITION OF ZURVITA'S ASSETS FOLLOWING SUCCESSFUL CHAPTER 11 PROCESS

  • ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT JANUARY 2025

  • ZINZINO AB (PUBL.): ENTERS INTO AGREEMENT TO PROVIDE DIP FINANCING TO ZURVITA INITIATING CHAPTER 11 PROCESS